Could a single pill shorten the flu? new trial aims to find out

NCT ID NCT07314905

Not yet recruiting Symptom relief Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a single dose of baloxavir helps non-hospitalized adults with mild-to-moderate influenza recover faster compared to a placebo. About 264 participants will be enrolled within 5 days of symptoms and tracked until they feel fully recovered. The study is part of a larger platform trial that can adapt to test other respiratory treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baloxavir (a single-dose antiviral pill)
What this could lead to: If it works, this could provide a simple, one-dose treatment to help people recover faster from the flu at home.
What could go wrong: This is an early-stage sub-study within a larger platform trial, so results are uncertain. Baloxavir may not speed recovery more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY INFECTIONS (ARIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 influenza respiratory tract infectious disorder swine influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY INFECTIONS (ARIS) INFLUENZA A INFLUENZA B SAR-COV-2

Contacts and locations

Locations

Unity Health Toronto

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.